CAR039 Comprehensive Lipid Profile Testing in the Evaluation of ...

More documents

Recommendations

Info

APPLICABLE CODES The codes listed in this policy are for reference purposes only. Listing of a service or device code in this policy does not imply that the service described by this code is a covered or non-covered health service. Coverage is determined by the benefit document. This list of codes may not be all inclusive. CPT ® Code Description Lipid panel This panel must include the following: Cholesterol, serum, total 80061 (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478) 82465 Cholesterol, serum or whole blood, total 83090 Homocysteine 83695 Lipoprotein (a) 83698 Lipoprotein-associated phospholipase A2 (Lp-PLA2) 83700 Lipoprotein, blood; electrophoretic separation and quantitation Lipoprotein, blood; high resolution fractionation and quantitation of 83701 lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation) 83704 Lipoprotein, blood; quantitation of lipoprotein particle numbers and lipoprotein particle subclasses (eg, by nuclear magnetic resonance spectroscopy) 83718 Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) 83719 VLDL cholesterol 83721 Lipoprotein, direct measurement; LDL cholesterol 83727 Luteinizing releasing factor (LRH) 84478 Triglycerides CPT ® is a registered trademark of the American Medical Association. REFERENCES Davidson, M. Proise, Challenges,and Disappointments. Apolipoprotein A1 Therapy. Am Coll Cardiol, 2011; 57:1120-1121. Brewer Jr. HB, et al. Genetic dyslipoproteinemias. In: Pusler V, Ross R, Topol FJ eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996;69-88 .(3) Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease Curr Opin Lipidol 2010;21:289-297. Brunzell, JD et al. Diabetes Care, 2008 Apr;31(4):811-22. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Ridker P, et al: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2005; 107(3):391-7. Comprehensive Lipid Profile Testing in the Evaluation of Cardiovascular Disease Page 12 of 14
Pearson TA, et al: Markers of inflammation and cardiovascular disease: application to clinical and public healt practice. A statement for healhtcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511. Armitage JM, Bowman L, Clarke RJ, et al; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303:2486–9. Martí-Carvajal AJ, Sola I, Lathyris D, et al. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009; 4:CD006612 Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol 2008;51:449-455 Assimes TL, Hólm H, Kathiresan S, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies J Am Coll Cardiol 2010;56:1552-1563 Arsenalt BJ et al. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-57. Epub 2011 Dec 1. Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults (May 2001). "Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)". JAMA: the Journal of the American Medical Association 285 (19): 2486– 97. Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated Lipoprotein (a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339. Isser HS et al. Lipoprotein (a) and lipid levels in young patients with myocardial infarction and their first-degree relatives. Indian Heart J. 2001 Jul-Aug;53(4):463-6. Cardiovascular risk reduction in atherogenic dyslipidemia: Beyond LDL-C and statins. The European Atherosclerosis Society Press Release. Accessed March 2012. http://www.eas-society.org/consensusposition-paper-initiative.aspx Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Eng J Med 2000;343(16):1148-55. Comprehensive Lipid Profile Testing in the Evaluation of Cardiovascular Disease Page 13 of 14
Page 1 and 2: COMPREHENSIVE LIPID PROFILE TESTING
Page 3 and 4: Indications and Limitations of Cove
Page 5 and 6: is well known that CAD alone is the
Page 7 and 8: Apolipoproteins are proteins on the
Page 9 and 10: However, a recent study questioned
Page 11: H. LDL Particle Number. LDL particl

CAR039 Comprehensive Lipid Profile Testing in the Evaluation of ...

Create successful ePaper yourself

Delete template?

Save as template?